European Interleukin Inhibitors Market

European Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Product Type (IL-1 Inhibitors, IL-5 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors), and by Application (Arthritis, Asthma, Eczema, Inflammatory Bowel Disease (IBD), Psoriasis, and Others) Forecast, 2021-2027
    Update Available - Forecast 2024-2030   

Published: May 2021 | Report Code: OMR2023419 | Category : Pharmaceuticals | Delivery Format: /

The European Interleukin Inhibitors market is projected to grow at a modest CAGR of 8.4% during the forecast period (2021-2027). The major aspect that drives the growth of the market includes the higher rate and prevalence of various diseases arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and others. As per Asthma UK, about 5.4 million people have asthma-related problems in the UK out of which 1.1 million are children. The UK experience about 3 mortalities each day due to asthma. The NHS is spending near to 1 billion a year for the treatment and care of people with asthma-related diseases. A significant number of companies, research, the patient base has been observed in the market due to which a significant growth can be observed in the market over the forecast period.

The European Interleukin Inhibitors market is segmented on the basis of product type and applications. Based on the product type, the market is segmented as IL-1 inhibitors, IL-5 inhibitors, IL-6 inhibitors, IL-17 inhibitors, and IL-23 inhibitors. The IL-17 inhibitors segment is likely to register a significant market value over the forecast period. Based on the applications, the market is segmented as arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and others. The psoriasis segment is likely to register a significant market value over the forecast period.

Further, based on the geography, the European Interleukin Inhibitors market is segmented as the UK, Germany, France, Italy, Spain, and the Rest of Europe. The UK is likely to hold a most substantial share in the market attributing to the presence of the key market giants in the region. Furthermore, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KgaA, AstraZeneca Plc, and Sun Pharmaceutical Industries Ltd. are some of the prominent players functioning in the European Interleukin Inhibitors market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market. 

RESEARCH METHODOLOGY

The market study of the European Interleukin Inhibitors market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include:

  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report is intended for Interleukin Inhibitors manufacturers, pharmaceutical companies, and other related companies, along with government organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

  1. European Interleukin Inhibitors Market Research and Analysis by Product Type
  2. European Interleukin Inhibitors Market Research and Analysis by Applications

The Report covers:

  • Comprehensive research methodology of the European Interleukin Inhibitors market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the European Interleukin Inhibitors market.
  • Insights about market determinants which are stimulating the European Interleukin Inhibitors market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.

1. Report Summary

1.1. Research Methods and Tools

1.2. Market Breakdown

1.2.1. By Segments

2. Market Overview and Insights

2.1. Scope of the Report

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

3. Competitive Landscape

3.1. Competitive Dashboard

3.2. Key Strategy Analysis

3.3. Key Company Analysis

3.3.1. Overview

3.3.2. Financial Analysis 

3.3.3. SWOT Analysis

3.3.4. Recent Developments

3.3.5. Recent Developments

4. Market Determinants

4.1. Motivators

4.2. Restraints

4.3. Opportunities

5. Market Segmentation

5.1. European Interleukin Inhibitors Market by Product Type

5.1.1. IL-1 Inhibitors

5.1.2. IL-5 Inhibitors

5.1.3. IL-6 Inhibitors

5.1.4. IL-17 Inhibitors

5.1.5. IL-23 Inhibitors

5.2. European Interleukin Inhibitors Market by Application

5.2.1. Arthritis

5.2.2. Asthma

5.2.3. Eczema

5.2.4. Inflammatory Bowel Disease (IBD)

5.2.5. Psoriasis

5.2.6. Others (Transplant Rejection)

6. Regional Analysis

6.1. Europe

6.1.1. UK

6.1.2. Germany

6.1.3. France

6.1.4. Italy

6.1.5. Spain 

6.1.6. Rest of Europe

7. Company Profiles 

7.1. AbbVie, Inc.

7.2. AstraZeneca Plc

7.3. Bausch Health Co. Inc.

7.4. Bristol–Myers Squibb Co.

7.5. Eli Lilly and Co.

7.6. F. Hoffmann-La Roche Ltd.

7.7. GlaxoSmithKline Plc

7.8. Johnson and Johnson Services Inc. 

7.9. Merck KgaA

7.10. Novartis AG

7.11. Regeneron Pharmaceuticals, Inc.

7.12. Sanofi SA

7.13. Sun Pharmaceutical Industries Ltd.

7.14. Teva Pharmaceuticals Industries, Ltd

7.15. Valeant Pharmaceuticals, Inc.

1. EUROPEAN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)

2. EUROPEAN IL-1 INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

3. EUROPEAN IL-5 INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

4. EUROPEAN IL-6 INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

5. EUROPEAN IL-17 INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

6. EUROPEAN IL-23 INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

7. EUROPEAN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)

8. EUROPEAN INTERLEUKIN INHIBITORS FOR ARTHRITIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

9. EUROPEAN INTERLEUKIN INHIBITORS FOR ASTHMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

10. EUROPEAN INTERLEUKIN INHIBITORS FOR ECZEMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

11. EUROPEAN INTERLEUKIN INHIBITORS FOR INFLAMMATORY BOWEL DISEASE (IBD) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

12. EUROPEAN INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

13. EUROPEAN INTERLEUKIN INHIBITORS FOR OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

14. EUROPEAN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

15. UK INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)

16. UK INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)

17. GERMANY INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)

18. GERMANY INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)

19. FRANCE INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)

20. FRANCE INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)

21. ITALY INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)

22. ITALY INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)

23. SPAIN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)

24. SPAIN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)

25. REST OF EUROPE INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)

26. REST OF EUROPE INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)

1. EUROPEAN INTERLEUKIN INHIBITORS MARKET SHARE BY PRODUCT TYPE, 2020 VS 2027 (%)

2. EUROPEAN INTERLEUKIN INHIBITORS MARKET SHARE BY APPLICATION, 2020 VS 2027 (%)

3. EUROPEAN INTERLEUKIN INHIBITORS MARKET SHARE BY COUNTRY, 2020 VS 2027 (%)

4. UK INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)

5. GERMANY INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)

6. FRANCE INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)

7. ITALY INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)

8. SPAIN INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)

9. REST OF EUROPE INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)